GlassScriptPhysician profile
Dylan J Dangerfield
NPI 1245791128
$728.24
in general payments reported to CMS, 2019-2025
13 companies · $240 in 2025
The $240 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $488 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $728.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $172.48 | 2024 | Ams 700 |
| Coloplast Corp | $124.01 | 2024-2025 | |
| Astellas Pharma US INC | $70.66 | 2024-2025 | Xtandi |
| Axonics, INC. | $69.61 | 2024 | Axonics, Bulkamid |
| Pfizer INC. | $48.66 | 2025 | |
| Procept Biorobotics Corporation | $48.40 | 2024 | Aquabeam System |
| Urogen Pharma, INC. | $45.84 | 2024 | |
| Olympus America INC. | $40.54 | 2025 | Itind System |
| Sumitomo Pharma America, INC. | $38.80 | 2024-2025 | Gemtesa, Orgovyx |
| Progenics Pharmaceuticals, INC. | $19.84 | 2025 | |
| Accord Healthcare, INC. | $19.25 | 2024 | |
| Teleflex LLC | $16.06 | 2025 | Barrigel |
| Photocure INC | $14.09 | 2024 | Cysview |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dylan Dangerfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.